Author:
Shi Wei-li,Liu Zhong-zhen,Wang Hong-dan,Wu Dong,Zhang Hui,Xiao Hai,Chu Yan,Hou Qiao-fang,Liao Shi-xiu
Funder
Natural Science Foundation of China
Science and Technology Development Program of Henan Science and Technology Department
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Biochemistry (medical),Cell Biology,Clinical Biochemistry,Molecular Biology,General Medicine,Endocrinology, Diabetes and Metabolism
Reference27 articles.
1. Carothers AD, Hecht CA, Hook EB. International variation in reported livebirth prevalence rates of Down syndrome, adjusted for maternal age. J Med Genet. 1999;36(5):386–93.
2. Sinet PM, Theophile D, Rahmani Z, Chettouh Z, Blouin JL, Prieur M, et al. Mapping of the Down syndrome phenotype on chromosome 21 at the molecular level. Biomed Pharmacother. 1994;48(5–6):247–52.
3. Gardiner KJ. Molecular basis of pharmacotherapies for cognition in Down syndrome. Trends Pharmacol Sci. 2010;31(2):66–73. doi: 10.1016/j.tips.2009.10.010 .
4. Wisniewski KE, Dalton AJ, McLachlan C, Wen GY, Wisniewski HM. Alzheimer’s disease in Down’s syndrome: clinicopathologic studies. Neurology. 1985;35(7):957–61.
5. Jones EL, Ballard CG, Prasher VP, Arno M, Tyrer S, Moore B, et al. An Intron 7 Polymorphism in APP Affects the Age of Onset of Dementia in Down Syndrome. Int J Alzheimers Dis. 2010;2011:929102. doi: 10.4061/2011/929102 .
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献